Do analysts rate XCUR or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, XCUR or CDT?

Exicure has higher revenue and earnings than CDT Equity. Exicure is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 37.71 -$4.95M -$1.55 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is XCUR or CDT more profitable?

Exicure's return on equity of -179.41% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% CDT Equity N/A -4,263.33% -529.91%

Does the media refer more to XCUR or CDT?

In the previous week, CDT Equity had 1 more articles in the media than Exicure. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for Exicure. Exicure's average media sentiment score of 1.25 beat CDT Equity's score of 0.29 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, KTTA or CDT?

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pasithea Therapeutics N/A N/A -$20.43M -$2.08 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is KTTA or CDT more profitable?

Pasithea Therapeutics' return on equity of -57.44% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Pasithea Therapeutics N/A -57.44% -53.61% CDT Equity N/A -4,263.33% -529.91%

Does the media refer more to KTTA or CDT?

In the previous week, CDT Equity had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.29 beat CDT Equity's score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CDT or NCEL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, CDT or NCEL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A NLS Pharmaceutics N/A N/A -$8.30M N/A N/A

Is CDT or NCEL more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% NLS Pharmaceutics N/A N/A N/A

Do analysts rate CDT or INAB?

IN8bio has a consensus target price of $4.00, suggesting a potential upside of 159.74%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, CDT or INAB?

IN8bio is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is CDT or INAB more profitable?

IN8bio's return on equity of -96.39% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -4,263.33% -529.91% IN8bio N/A -96.39% -80.18%

Does the media refer more to CDT or INAB?

In the previous week, CDT Equity and CDT Equity both had 4 articles in the media. IN8bio's average media sentiment score of 0.54 beat CDT Equity's score of 0.29 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZIVO or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ZIVO or CDT?

ZIVO Bioscience has higher revenue and earnings than CDT Equity. ZIVO Bioscience is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZIVO Bioscience $15.85K 973.17 -$7.78M -$1.71 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is ZIVO or CDT more profitable?

ZIVO Bioscience's return on equity of 0.00% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% CDT Equity N/A -4,263.33% -529.91%

Does the media favor ZIVO or CDT?

In the previous week, CDT Equity had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for ZIVO Bioscience. CDT Equity's average media sentiment score of 0.29 beat ZIVO Bioscience's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CDT Equity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CDT Equity (CDT) Competitors

$0.85 +0.05 (+5.59%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 -0.03 (-3.18%)

As of 07:50 PM Eastern

Compare

CDT vs. XCUR, KTTA, NCEL, INAB, and ZIVO

Should you buy CDT Equity stock or one of its competitors? MarketBeat compares CDT Equity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CDT Equity include Exicure (XCUR), Pasithea Therapeutics (KTTA), NLS Pharmaceutics (NCEL), IN8bio (INAB), and ZIVO Bioscience (ZIVO). These companies are all part of the "pharmaceutical products" industry.

How does CDT Equity compare to Exicure?

Exicure (NASDAQ:XCUR) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Exicure's return on equity of -179.41% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
CDT Equity	N/A	-4,263.33%	-529.91%

Exicure has higher revenue and earnings than CDT Equity. Exicure is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	37.71	-$4.95M	-$1.55	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Exicure has a beta of 3.53, suggesting that its share price is 253% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 10.8% of CDT Equity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, CDT Equity had 1 more articles in the media than Exicure. MarketBeat recorded 4 mentions for CDT Equity and 3 mentions for Exicure. Exicure's average media sentiment score of 1.25 beat CDT Equity's score of 0.29 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Exicure beats CDT Equity on 9 of the 10 factors compared between the two stocks.

How does CDT Equity compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, CDT Equity had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 4 mentions for CDT Equity and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.29 beat CDT Equity's score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pasithea Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Pasithea Therapeutics' return on equity of -57.44% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
CDT Equity	N/A	-4,263.33%	-529.91%

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Pasithea Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 383.87%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Pasithea Therapeutics is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pasithea Therapeutics beats CDT Equity on 9 of the 12 factors compared between the two stocks.

How does CDT Equity compare to NLS Pharmaceutics?

CDT Equity (NASDAQ:CDT) and NLS Pharmaceutics (NASDAQ:NCEL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

3.3% of CDT Equity shares are held by institutional investors. 10.8% of CDT Equity shares are held by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NLS Pharmaceutics' return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
NLS Pharmaceutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A

CDT Equity has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, NLS Pharmaceutics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

In the previous week, CDT Equity had 4 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.87 beat CDT Equity's score of 0.29 indicating that NLS Pharmaceutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CDT Equity	Neutral
NLS Pharmaceutics	Very Positive

Summary

NLS Pharmaceutics beats CDT Equity on 5 of the 8 factors compared between the two stocks.

How does CDT Equity compare to IN8bio?

CDT Equity (NASDAQ:CDT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

IN8bio's return on equity of -96.39% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-4,263.33%	-529.91%
IN8bio	N/A	-96.39%	-80.18%

IN8bio has a consensus target price of $4.00, suggesting a potential upside of 159.74%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CDT Equity and CDT Equity both had 4 articles in the media. IN8bio's average media sentiment score of 0.54 beat CDT Equity's score of 0.29 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IN8bio is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

CDT Equity has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Summary

IN8bio beats CDT Equity on 10 of the 11 factors compared between the two stocks.

How does CDT Equity compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CDT Equity had 3 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for ZIVO Bioscience. CDT Equity's average media sentiment score of 0.29 beat ZIVO Bioscience's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CDT Equity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ZIVO Bioscience has higher revenue and earnings than CDT Equity. ZIVO Bioscience is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	973.17	-$7.78M	-$1.71	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZIVO Bioscience's return on equity of 0.00% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
CDT Equity	N/A	-4,263.33%	-529.91%

ZIVO Bioscience has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Summary

ZIVO Bioscience beats CDT Equity on 6 of the 11 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.91M	$2.97B	$6.44B	$12.46B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	N/A	18.12	23.87	24.36
Price / Sales	N/A	303.59	521.52	117.01
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	-0.01	3.95	9.99	6.73
Net Income	-$39.22M	$75.85M	$3.56B	$337.03M
7 Day Performance	-10.54%	-1.13%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-99.84%	23.03%	28.76%	33.98%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.2838 of 5 stars	$0.85 +5.6%	N/A	-99.9%	$3.91M	N/A	N/A	3	Gap Up
XCUR Exicure	1.2277 of 5 stars	$2.67 -5.0%	N/A	-70.3%	$17.01M	$500K	N/A	50	Positive News Earnings Report Short Interest Decrease Gap Down
KTTA Pasithea Therapeutics	2.841 of 5 stars	$0.68 -2.8%	$3.00 +341.1%	-30.6%	$16.96M	N/A	N/A	3	Positive News Analyst Upgrade
NCEL NLS Pharmaceutics	1.5514 of 5 stars	$3.15 -0.3%	N/A	-85.0%	$16.85M	N/A	N/A	6	Gap Up
INAB IN8bio	3.8737 of 5 stars	$1.69 +1.2%	$4.00 +136.7%	-58.5%	$16.65M	N/A	N/A	20	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. XCUR, KTTA, NCEL, INAB, and ZIVO

How does CDT Equity compare to Exicure?

Summary

How does CDT Equity compare to Pasithea Therapeutics?

Summary

How does CDT Equity compare to NLS Pharmaceutics?

Summary

How does CDT Equity compare to IN8bio?

Summary

How does CDT Equity compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. XCUR, KTTA, NCEL, INAB, and ZIVO

How does CDT Equity compare to Exicure?

Is XCUR or CDT more profitable?

Which has preferable earnings & valuation, XCUR or CDT?

Which has more volatility and risk, XCUR or CDT?

Do insiders & institutionals have more ownership in XCUR or CDT?

Does the media refer more to XCUR or CDT?

Do analysts rate XCUR or CDT?

Summary

How does CDT Equity compare to Pasithea Therapeutics?

Does the media refer more to KTTA or CDT?

Do insiders and institutionals believe in KTTA or CDT?

Which has more volatility & risk, KTTA or CDT?

Is KTTA or CDT more profitable?

Which has better valuation and earnings, KTTA or CDT?

Do analysts rate KTTA or CDT?

Summary

How does CDT Equity compare to NLS Pharmaceutics?

Do insiders & institutionals believe in CDT or NCEL?

Do analysts rate CDT or NCEL?

Is CDT or NCEL more profitable?

Which has higher earnings & valuation, CDT or NCEL?

Which has more risk and volatility, CDT or NCEL?

Does the media refer more to CDT or NCEL?

Summary

How does CDT Equity compare to IN8bio?

Is CDT or INAB more profitable?

Do analysts rate CDT or INAB?

Do institutionals and insiders believe in CDT or INAB?

Does the media refer more to CDT or INAB?

Which has preferable earnings and valuation, CDT or INAB?

Which has more volatility and risk, CDT or INAB?

Summary

How does CDT Equity compare to ZIVO Bioscience?

Do insiders and institutionals have more ownership in ZIVO or CDT?

Does the media favor ZIVO or CDT?

Which has higher valuation and earnings, ZIVO or CDT?

Do analysts rate ZIVO or CDT?

Is ZIVO or CDT more profitable?

Which has more risk & volatility, ZIVO or CDT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools